{"id":"W4411135651","doi":"10.1016/j.esmoop.2025.105125","title":"Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Foundation Medicine; Bayer Yakuhin; MSD K.K.; Chugai Pharmaceutical; Pfizer Japan; EMD Serono; AstraZeneca; Genentech; Council of Scientific and Industrial Research, India; Sierra Oncology; Sanofi K.K.; INCLIVA Instituto de Investigación Sanitaria; Exelixis; International Atomic Energy Agency; PharmaMar; Daiichi Sankyo Europe; Takeda Oncology; European Society for Medical Oncology; Novocure; Seoul National University; Indian Council of Medical Research; Intas Pharmaceuticals; Seagen; European SocieTy for Radiotherapy and Oncology; Glenmark Pharmaceuticals; The Wellcome Trust DBT India Alliance; Seoul National University Hospital; MacroGenics; Sociedad Española de Oncología Médica; BeiGene; Actuate Therapeutics; Ribon Therapeutics; Sysmex Corporation; Mersana Therapeutics; Amgen; Astellas Pharma; Deciphera Pharmaceuticals; Clovis Oncology; Natera; Regeneron Pharmaceuticals; Boehringer Ingelheim Japan; Gilead Sciences; Taiho Pharmaceutical; EQRx; F. Hoffmann-La Roche; Servier; Eisai; FibroGen; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; American Society of Clinical Oncology; Hellenic Society of Medical Oncology; Sanofi; Pfizer; Celgene","keywords":"Guideline; Reimbursement; Medicine; Family medicine; China; Political science; Health care; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01156325,0.00104994,0.001525159,0.003391512,0.001124684,0.002533909,0.002901265,0.005061844,0.005463836],"category_scores_gemma":[0.03289583,0.0006325961,0.003356185,0.00291445,0.001141267,0.00187433,0.002860602,0.006671702,0.005209556],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004431926,"about_ca_system_score_gemma":0.01974653,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02049889,"about_ca_topic_score_gemma":0.0489886,"domain_scores_codex":[0.9870223,0.005257368,0.003705317,0.0004537888,0.002847342,0.0007139288],"domain_scores_gemma":[0.9735242,0.003818508,0.002019642,0.0005330578,0.01890919,0.001195323],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001209814,0.0001466318,0.003172241,0.004342988,0.0001778798,0.0007533358,0.0007380122,0.00115665,0.0008363089,0.006269037,0.8067711,0.1755148],"study_design_scores_gemma":[0.0002038736,0.0001257105,0.008221525,0.01504357,0.0002333693,0.001414943,0.0005016181,0.0008138068,0.0004522796,0.005806762,0.9670922,0.00009035823],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.008570671,0.1476112,0.07964771,0.4891224,0.02711854,0.01395649,0.02720029,0.001765619,0.2050071],"genre_scores_gemma":[0.0754022,0.2030825,0.3537549,0.1995748,0.009612398,0.02108411,0.06387826,0.0008913464,0.07271942],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.02049889,"threshold_uncertainty_score":0.06115305,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03089511936107969,"score_gpt":0.3789578666959741,"score_spread":0.3480627473348945,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}